Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05390892 · ClinicalTrials.gov registry record · Phase 4
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes and ASCVD, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 6,000
- Enrollment target
- 8
- Study locations
NCT05390892: Recruiting Phase 4 study of Type 2 Diabetes and ASCVD, sponsored by Brigham and Women's Hospital.
NCT05390892 is a Phase 4 study of Type 2 Diabetes and ASCVD that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 6,000 participants, above the 3,905-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (54% higher). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05390892, a Phase 4 study of Type 2 Diabetes and ASCVD, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 6,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.
Primary Outcome
total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor
- DRUG GLP-1 receptor agonist
Study Locations (8)
Maryland
- Johns Hopkins School of Medicine - Baltimore
Minnesota
- Essentia Health - Duluth
Missouri
- University of Missouri-Columbia - Columbia
New York
- Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University - New York
North Carolina
- Duke University Hospital - Durham
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- Vanderbilt University Medical Center - Nashville
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 4 |
What NCT05390892 shows while recruiting
NCT05390892 is an interventional study that assigns participants to a tested intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,905-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (54% higher).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which SGLT2 inhibitor is the first listed.
NCT05390892 lists 8 locations in 8 states (Maryland, Minnesota, Missouri).
Frequently Asked Questions
What is clinical trial NCT05390892 about?
NCT05390892 is a clinical study titled "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes". PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or...
What is the current status of trial NCT05390892?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 6,000 participants. The study started on 2022-09-26. Estimated completion is 2029-03-01.
What conditions does trial NCT05390892 study?
This clinical trial studies the following conditions: Type 2 Diabetes, ASCVD.
What interventions are being tested in trial NCT05390892?
The interventions under investigation include: SGLT2 inhibitor (DRUG), GLP-1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT05390892?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05390892 being conducted?
This trial has 8 study locations across Maryland, Minnesota, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05390892's enrollment target sits among peer trials
6,000 10th of 327 higher than 318 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI